



Sandostatin® LAR Depot (octreotide acetate) for injectable suspension, 20 mg

For Intragluteal Injection
Rx only
© NOVARTIS



For intragluteal injection

Rx Only



**Sandostatin® LAR Depot
(octreotide acetate) for injectable suspension, 20 mg**

For Intragluteal Injection

47358
3086A1



**Sandostatin® LAR Depot
(octreotide acetate) for injectable suspension, 20 mg**

For Intragluteal Injection



**Sandostatin® LAR Depot
(octreotide acetate) for injectable suspension,
for gluteal intramuscular use**



Rx only

© NOVARTIS

20

- Contents:
- One vial containing Sandostatin® LAR Depot
- One prefilled syringe containing diluent solution for reconstitution
- One vial adapter for drug product reconstitution
- One 1.5 x 19 gauge safety injection needle

20 mg
For intragluteal injection
NDC 0078-0818-81



**Sandostatin® LAR Depot
(octreotide acetate) for injectable suspension, 20 mg**

For intragluteal injection

0078-0818-81 N

(b)

(4)

- ATTENTION:**
- There are 3 critical steps in the reconstitution of Sandostatin LAR. **Not following them could result in failure to deliver the drug aseptically.**
 - **The injection kit must reach room temperature.** Remove the injection kit from the fridge and let the kit stand at room temperature for a minimum of 30 minutes before reconstitution, but no more than 24 hours.
 - After adding the diluent solution, **ensure that the vial is fully saturated by letting the vial stand for a minimum of 2 minutes and up to 5 minutes.**
 - After saturation, **shake the vial moderately in a horizontal direction for a minimum of 30 seconds until uniform suspension is formed.**



**Sandostatin® LAR Depot
(octreotide acetate) for injectable suspension, 20 mg**

For intragluteal injection

Each dilution contains:
Octreotide acetate 22.4 mg.
Sodium chloride 27.6 mg.
Dextrose 31.9 mg.
Water for injection 37.6 mg.

Product of Switzerland

STORAGE: Refrigerate at 2°C to 8°C (36°F to 46°F). Protect from light.
If you have any questions about storage, call 1-888-500-NOVA (1-888-500-6624).



**Sandostatin® LAR Depot
(octreotide acetate) for injectable suspension, 20 mg**


For intragluteal injection



**Sandostatin® LAR Depot
(octreotide acetate) for injectable suspension, 20 mg**

For intragluteal injection

0078-0818-81 N



**Sandostatin® LAR Depot
(octreotide acetate) for injectable suspension, 20 mg**

For intragluteal injection

0078-0818-81 N

(g)

Sandostatin® LAR Depot (octreotide acetate) for injectable suspension, for gluteal/intramuscular use

Rx only  NOVARTIS

30 mg
For Intragluteal Injection
NDC 0078-0825-81

ATTENTION:
There are 3 critical steps in the reconstitution of Sandostatin LAR. Not following them could result in failure to deliver the drug appropriately.
• The injection kit must reach room temperature. Remove the injection kit from the fridge and let the kit stand at room temperature for a minimum of 30 minutes before reconstitution, but do not exceed 24 hours.

* After adding the diluent solution, ensure that the powder is fully saturated by letting the vial stand for a minimum of 2 minutes and up to 5 minutes.
After saturation, shake the vial rapidly in a horizontal direction for a minimum of 30 seconds until uniform suspension is formed.

- Contents:
- One vial containing Sandostatin® LAR Depot
 - One prefilled syringe containing diluent solution for reconstitution
 - One vial adapter for drug product reconstitution
 - One 15^g x 19 gauge safety injection needle

Sandostatin® LAR Depot (octreotide acetate) for injectable suspension, 30 mg for gluteal/intramuscular use

For Intragluteal Injection

If you have any questions about Sandostatin LAR, please call 1-888-NOVARTIS (1-888-669-6693).

STORAGE: Refrigerate at 2°C to 8°C (36°F to 46°F). Protect from light.
N 078-0825-8 1

95 x 36 x 21.9

GTIN
EXP
LOT
SN

Sandostatin® LAR Depot (octreotide acetate) for injectable suspension, 30 mg for gluteal intramuscular use

For Intragluteal Injection

47358
3086A1



Sandostatin® LAR Depot (octreotide acetate) for injectable suspension, for gluteal/intramuscular use

 NOVARTIS
For Intragluteal Injection

(b) (4)

ATTENTION:

There are 3 critical steps in the reconstitution of Sandostatin LAR. Not following them could result in failure to deliver the drug appropriately.
• The injection kit must reach room temperature. Remove the injection kit from the fridge and let the kit stand at room temperature for a minimum of 30 minutes before reconstitution, but do not exceed 24 hours.
• After adding the diluent solution, ensure that the powder is fully saturated by letting the vial stand for a minimum of 2 minutes and up to 5 minutes.
• After saturation, shake the vial rapidly in a horizontal direction for a minimum of 30 seconds until uniform suspension is formed.

Each dilute syringe contains:
Carboxymethylcellulose sodium 14 mg
mannitol 12 mg
poloxamer 188 4 mg
water for injection 2 mL

Rx only

Product of Switzerland

Sandostatin® LAR Depot (octreotide acetate) for injectable suspension, for gluteal/intramuscular use

ATTENTION:

There are 3 critical steps in the reconstitution of Sandostatin LAR. Not following them could result in failure to deliver the drug appropriately.
• The injection kit must reach room temperature. Remove the injection kit from the fridge and let the kit stand at room temperature for a minimum of 30 minutes before reconstitution, but do not exceed 24 hours.
• After adding the diluent solution, ensure that the powder is fully saturated by letting the vial stand for a minimum of 2 minutes and up to 5 minutes.
• After saturation, shake the vial rapidly in a horizontal direction for a minimum of 30 seconds until uniform suspension is formed.

Sandostatin LAR Depot
Vials are manufactured by:
Sandoz GmbH,
Schaffhausen, Austria
(Subsidiary of Novartis Pharma AG)
Basel, Switzerland (d)
Diluent syringes are manufactured by:
Abbot Laboratories B.V.
Oost, The Netherlands
Distributed by:
Novartis Pharmaceuticals Corporation
East Hanover, New Jersey 07936
© Novartis

Sandostatin® LAR Depot (octreotide acetate) for injectable suspension, for gluteal/intramuscular use

For Intragluteal Injection

(b) (4)